DRF 7295

Drug Profile

DRF 7295

Alternative Names: DRF7295

Latest Information Update: 02 Oct 2015

Price : $50

At a glance

  • Originator Dabur Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 20 Apr 2008 Dabur Pharma has been acquired by Fresenius Kabi
  • 18 May 2007 Phase II development is ongoing
  • 31 Oct 2005 Phase-II clinical trials in Colorectal cancer in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top